Hyloris Pharmaceuticals prepared to go public
Belgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 392 entries.
Entries by Thomas Gabrielczyk
NodThera bags US$55m in Series B round
3rd June 2020 in News /by Thomas GabrielczykNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
2nd June 2020 in News /by Thomas GabrielczykAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
Novo Holdings invests into AI CRO ExScientia
27th May 2020 in News /by Thomas GabrielczykNovo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.
Poxel SA raises 17.7m through capital increase
26th May 2020 in News /by Thomas GabrielczykMetabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at 0.02 per share reserved to specified investors.
British scientists start Phase II on COVID-19 vaccine
25th May 2020 in News /by Thomas GabrielczykResearchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
New algorithm predicts rheumatoid arthritis
25th May 2020 in News /by Thomas GabrielczykBased on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
SARS-CoV2 antibody tests: not suited for individual diagnosis?
20th May 2020 in News /by Thomas GabrielczykAn international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Vaccine to protect from any viral infection
19th May 2020 in News /by Thomas GabrielczykTwo companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
Abivax bags 36m fund for COVID-19 programme
18th May 2020 in News /by Thomas GabrielczykFrench Abivax SA has received a 36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.